ACTIVITY OVERVIEW | prIME Oncology presents an educational monograph on emerging immunotherapies for non-small cell lung cancer. This monograph covers three key topics: the immunomodulatory protein talactoferrin, the anti-CTLA-4 antibody ipilimumab, and a vaccine targeting MAGE-A3. |
AUTHORS | Nicholas Thatcher, MD, PhD
The Christie Hospital
Manchester, United Kingdom
Suresh Ramalingam, MD
Emory University
Atlanta, Georgia, United States
Román Pérez-Soler, MD
Montefiore Medical Center
Bronx, New York, United States
|
TARGET AUDIENCE | This educational monograph is intended for medical oncologists, radiation oncologists, thoracic surgeons,
pulmonologists, and other professionals actively involved in the management of patients with non-small
cell lung cancer. |
|
|
TABLE OF CONTENTS |
- Immunomodulatory Protein Talactoferrin
- Mechanism of Action and Preclinical Data
- Clinical Activity and Safety
- Phase III Trials of Talactoferrin in NSCLC
- Talactoferrin in Severe Sepsis
- Anti-CTLA-4 Antibody Ipilimumab
- Results with Ipilimumab in Melanoma
- Ipilimumab in NSCLC
- MAGE-A3 Vaccine
- Mechanism of Action
- Efficacy Results from Phase II Trials
- Ongoing Phase III Trial
|
LEARNING OBJECTIVES | Upon completion of this educational activity, participants should be able to:
- Discuss the rationale for development of immunotherapeutic agents for the treatment of NSCLC
- Evaluate recent clinical trial data on the efficacy and safety of immunotherapy for patients with NSCLC
- Examine the potential utility of emerging immunotherapeutic strategies for lung cancer, and determine
how best to integrate these strategies into current standards of care
|
|
|
|
This is a prIME Oncology activity.
SUPPORT | This monograph is supported by an educational grant from Agennix.
|
|
